Display options
Cite
Wu L, Baylan U, van der Leeden B, et al. Cardiac inflammation and microvascular procoagulant changes are decreased in second wave compared to first wave deceased COVID-19 patients. Int J Cardiol. 2021;doi: 10.1016/j.ijcard.2021.11.079.
Wu, L., Baylan, U., van der Leeden, B., Schurink, B., Roos, E., Schalkwijk, C. G., Bugiani, M., van der Valk, P., van Rossum, A. C., Zeerleder, S. S., Heunks, L. M. A., Boon, R. A., de Boer, O. J., van der Wal, A. C., Niessen, H. W. M., & Krijnen, P. A. J. (2021). Cardiac inflammation and microvascular procoagulant changes are decreased in second wave compared to first wave deceased COVID-19 patients. International journal of cardiology, . https://doi.org/10.1016/j.ijcard.2021.11.079
Wu, Linghe, et al. "Cardiac inflammation and microvascular procoagulant changes are decreased in second wave compared to first wave deceased COVID-19 patients." International journal of cardiology vol. (2021). doi: https://doi.org/10.1016/j.ijcard.2021.11.079
Wu L, Baylan U, van der Leeden B, Schurink B, Roos E, Schalkwijk CG, Bugiani M, van der Valk P, van Rossum AC, Zeerleder SS, Heunks LMA, Boon RA, de Boer OJ, van der Wal AC, Niessen HWM, Krijnen PAJ. Cardiac inflammation and microvascular procoagulant changes are decreased in second wave compared to first wave deceased COVID-19 patients. Int J Cardiol. 2021 Dec 03; doi: 10.1016/j.ijcard.2021.11.079. Epub 2021 Dec 03. PMID: 34871622; PMCID: PMC8641429.
Copy Download .nbib Format: NLM
Share it on

Int J Cardiol. 2021 Dec 03; doi: 10.1016/j.ijcard.2021.11.079. Epub 2021 Dec 03.

Cardiac inflammation and microvascular procoagulant changes are decreased in second wave compared to first wave deceased COVID-19 patients.

International journal of cardiology

Linghe Wu, Umit Baylan, Britt van der Leeden, Bernadette Schurink, Eva Roos, Casper G Schalkwijk, Marianna Bugiani, Paul van der Valk, Albert C van Rossum, Sacha S Zeerleder, Leo M A Heunks, Reinier A Boon, Onno J de Boer, Allard C van der Wal, Hans W M Niessen, Paul A J Krijnen

Affiliations

  1. Dept. of Pathology and Amsterdam Cardiovascular Sciences (ACS), Amsterdam University Medical Centre (AUMC), location VUmc, De Boelelaan 1017, 1081HV Amsterdam, the Netherlands.
  2. Dept. of Pathology and ACS, AUMC, location VUmc, the Netherlands.
  3. Dept. of Pathology and Amsterdam institute for Infection and Immunity, AUMC, the Netherlands.
  4. Dept. of Pathology, AUMC, location VUmc, the Netherlands.
  5. Dept. of Internal Medicine and Cardiovascular Research Institute Maastricht, Maastricht University Medical Centre, P. Debyelaan 25, 6229 HX, Maastricht, the Netherlands.
  6. Dept. of Pathology, AUMC, location VUmc and AMC, Meibergdreef 9, 1105 AZ Amsterdam, the Netherlands.
  7. Dept. of Cardiology and ACS, AUMC, location VUmc, the Netherlands.
  8. Dept. of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, Freiburgstrasse 18, 3010 Bern, Switzerland; Dept. for BioMedical Research, University of Bern, Murtenstrasse 35, 3008 Bern, Switzerland.
  9. Dept. Intensive Care Medicine, AUMC, location VUmc, the Netherlands.
  10. German Center for Cardiovascular Research (DZHK), Goethe University, Frankfurt am Main, Germany; German Center for Cardiovascular Research (DZHK), Goethe University, Frankfurt am Main, Germany.
  11. Dept. of Pathology and ACS, AUMC, location AMC, the Netherlands.
  12. Dept. of Pathology and ACS and Dept. of Cardiac Surgery, AUMC, location VUmc, the Netherlands.
  13. Dept. of Pathology and ACS, AUMC, location VUmc, the Netherlands. Electronic address: [email protected].

PMID: 34871622 PMCID: PMC8641429 DOI: 10.1016/j.ijcard.2021.11.079

Abstract

BACKGROUND: Compelling evidence has shown cardiac involvement in COVID-19 patients. However, the overall majority of these studies use data obtained during the first wave of the pandemic, while recently differences have been reported in disease course and mortality between first- and second wave COVID-19 patients. The aim of this study was to analyze and compare cardiac pathology between first- and second wave COVID-19 patients.

METHODS: Autopsied hearts from first- (n = 15) and second wave (n = 10) COVID-19 patients and from 18 non-COVID-19 control patients were (immuno)histochemically analyzed. CD45+ leukocyte, CD68+ macrophage and CD3+ T lymphocyte infiltration, cardiomyocyte necrosis and microvascular thrombosis were quantified. In addition, the procoagulant factors Tissue Factor (TF), Factor VII (FVII), Factor XII (FXII), the anticoagulant protein Dipeptidyl Peptidase 4 (DPP4) and the advanced glycation end-product N(

RESULTS: Cardiac inflammation was significantly decreased in second wave compared to first wave COVID-19 patients, predominantly related to a decrease in infiltrated lymphocytes and the occurrence of lymphocytic myocarditis. This was accompanied by significant decreases in cardiomyocyte injury and microvascular thrombosis. Moreover, microvascular deposits of FVII and CML were significantly lower in second wave compared to first wave COVID-19 patients.

CONCLUSIONS: These results show that in our cohort of fatal COVID-19 cases cardiac inflammation, cardiomyocyte injury and microvascular thrombogenicity were markedly decreased in second wave compared to first wave patients. This may reflect advances in COVID-19 treatment related to an increased use of steroids in the second COVID-19 wave.

Copyright © 2021 The Author. Published by Elsevier B.V. All rights reserved.

Keywords: COVID-19; First and second wave; Heart; Inflammation; Thrombosis microvasculature

Conflict of interest statement

Declaration of Competing Interest None.

References

  1. Prog Cardiovasc Dis. 2020 Sep - Oct;63(5):682-689 - PubMed
  2. J Am Coll Cardiol. 2021 Jan 26;77(3):314-325 - PubMed
  3. J Infect. 2021 Apr;82(4):84-123 - PubMed
  4. Circulation. 2021 Mar 9;143(10):1031-1042 - PubMed
  5. Nature. 2021 Jul;595(7869):707-712 - PubMed
  6. Ann Intern Med. 2020 Aug 18;173(4):268-277 - PubMed
  7. Shock. 2007 Jan;27(1):10-8 - PubMed
  8. Circulation. 2008 Jan 1;117(1):43-51 - PubMed
  9. Lancet Respir Med. 2020 Jun;8(6):e46-e47 - PubMed
  10. Eur J Heart Fail. 2020 May;22(5):911-915 - PubMed
  11. Heart. 2008 Apr;94(4):450-6 - PubMed
  12. JAMA Cardiol. 2020 Jul 1;5(7):819-824 - PubMed
  13. Cardiovasc Pathol. 2021 Sep-Oct;54:107361 - PubMed
  14. Br J Cancer. 2007 Mar 26;96(6):937-43 - PubMed
  15. Circulation. 2021 Jan 19;143(3):230-243 - PubMed
  16. Circulation. 2020 Aug 25;142(8):804-809 - PubMed
  17. Arch Biochem Biophys. 1982 Sep;217(2):748-50 - PubMed
  18. Lancet Respir Med. 2021 May;9(5):e47-e48 - PubMed
  19. N Engl J Med. 2021 Aug 26;385(9):790-802 - PubMed
  20. JAMA Cardiol. 2020 Nov 1;5(11):1265-1273 - PubMed
  21. ESC Heart Fail. 2020 Oct;7(5):2440-2447 - PubMed
  22. Eur Heart J Cardiovasc Imaging. 2021 Jul 20;22(8):844-851 - PubMed
  23. Transbound Emerg Dis. 2021 Mar;68(2):213-215 - PubMed
  24. JAMA Cardiol. 2020 Nov 1;5(11):1281-1285 - PubMed
  25. N Engl J Med. 2021 Aug 26;385(9):777-789 - PubMed
  26. JAMA Cardiol. 2020 Jul 1;5(7):802-810 - PubMed
  27. Eur Heart J. 2020 May 14;41(19):1861-1862 - PubMed
  28. Crit Care. 2009;13(3):R87 - PubMed
  29. Chaos. 2021 Mar;31(3):031105 - PubMed
  30. PLoS One. 2021 Mar 31;16(3):e0248029 - PubMed
  31. Arterioscler Thromb Vasc Biol. 2006 Nov;26(11):2497-503 - PubMed
  32. Eur Heart J. 2020 Oct 14;41(39):3827-3835 - PubMed
  33. Lancet Microbe. 2020 Nov;1(7):e290-e299 - PubMed
  34. Eur Heart J. 1995 Dec;16 Suppl O:168-72 - PubMed
  35. Cardiovasc Pathol. 2021 Jan - Feb;50:107300 - PubMed
  36. Crit Care Explor. 2021 Feb 22;3(2):e0346 - PubMed
  37. Basic Res Cardiol. 2012 Jan;107(1):233 - PubMed
  38. Hum Pathol. 2017 Apr;62:83-90 - PubMed
  39. Eur Heart J. 2013 Sep;34(33):2636-48, 2648a-2648d - PubMed
  40. Arterioscler Thromb Vasc Biol. 2020 Sep;40(9):2033-2044 - PubMed

Publication Types